methyl 5-(aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: methyl 5-(aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylate
• 英文别名: methyl 1-methyl-5-sulfamoyl-1H-pyrrole-2-carboxylate；Methyl 1-methyl-5-sulfamoylpyrrole-2-carboxylate
• 化学式: C₇H₁₀N₂O₄S
• 分子量: 218.233
• InChiKey: ATVGJQIJFTXZOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  99.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-(氨基磺酰基)-1-甲基-1H-吡咯-2-羧酸 、 三甲基硅烷化重氮甲烷 以 甲醇 、 甲苯 为溶剂， 反应 3.0h， 以61%的产率得到methyl 5-(aminosulfonyl)-1-methyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  WO2007/23186

  摘要：

  公开号：

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Kunzer Aaron R.

  公开号：US20100184766A1

  公开（公告）日：2010-07-22

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  公开了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白疾病的方法。
• Pyrazine Derivatives and Use as P13k Inhibitors
  申请人：Gaillard Pascale

  公开号：US20090082356A1

  公开（公告）日：2009-03-26

  The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及式（I）的吡嗪衍生物，特别用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺部损伤。
• Pyrazine compounds and uses as PI3K inhibitors
  申请人：Merck Serono SA

  公开号：US08071597B2

  公开（公告）日：2011-12-06

  The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及式（I）的吡嗪衍生物，特别用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。
• TRIAZOLE DERIVATIVE
  申请人：ONO Naoya

  公开号：US20110269960A1

  公开（公告）日：2011-11-03

  An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P 1 ), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below (where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO 2 —, or the like, R 1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R 1A represents a hydrogen atom or the like, R 2 represents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, R 3 represents an aryl group, R 4 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and R 5 represents an alkyl group having 1-10 carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).

  本发明的目的是提供一种化合物，具有抑制S1P与其受体Edg-1（S1P1）结合的作用，并且可用作制药化合物。该化合物或其药学上可接受的盐，该化合物由以下公式表示（其中A表示氧原子、硫原子、由公式-SO-表示的基团、由公式-SO2-表示的基团或类似的基团，R1表示氢原子、具有1-6个碳原子的烷基或类似的基团，R1A表示氢原子或类似的基团，R2表示具有1-6个碳原子的烷基、具有3-6个碳原子的环烷基或类似的基团，R3表示芳基基团，R4表示氢原子或具有1-6个碳原子并且可选地带有羧基的烷基基团，R5表示具有1-10个碳原子的烷基、具有3-8个碳原子的环烷基、可选地被取代的芳基基团或类似的基团）。
• PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS
  申请人：Gaillard Pascale

  公开号：US20110312960A1

  公开（公告）日：2011-12-22

  The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及式（I）的吡嗪衍生物，特别是用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。